{"preliminary_commentary":{"by_channel":{"x_thread":21,"youtube":5,"podcast":5,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04472429\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["retifanlimab"]],"indication":"locally recurrent or metastatic squamous cell anal carcinoma","name":"InterAACT 2","nct_id":"NCT04472429","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=interaact-2-nct04472429. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and placebo on Day 1 of each 28 day cycle","label":"Group A : carboplatin+paclitaxel+placebo","type":"PLACEBO_COMPARATOR"},{"description":"Participants will receive carboplatin on Day 1,paclitaxel on Day1,8, 15, and retifanlimab on Day 1 of each 28 day cycle","label":"Group B : carboplatin+paclitaxel+retifanlimab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-09-26","type":"ACTUAL"},"conditions":["Squamous Cell Carcinoma of the Anal Canal"],"enrollment":{"count":308,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"carboplatin","otherNames":[],"type":"DRUG"},{"name":"paclitaxel","otherNames":[],"type":"DRUG"},{"name":"retifanlimab","otherNames":["INCMGA00012"],"type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Incyte Corporation","official_title":"A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-04-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS)","timeFrame":"up to 33.9 months"}],"references":[{"citation":"Rao S, Samalin-Scalzi E, Evesque L, Ben Abdelghani M, Morano F, Roy A, Dahan L, Tamberi S, Dhadda AS, Saunders MP, Casanova N, Guimbaud R, Lievre A, Maurel J, Fakih M, Tian C, Harrison J, Jones MM, Cornfeld M, Spano JP, Rochefort P; POD1UM-303/InterAACT-2 study investigators. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial. Lancet. 2025 Jun 14;405(10495):2144-2152. doi: 10.1016/S0140-6736(25)00631-2.","pmid":"40517007","type":"DERIVED"},{"citation":"Rao S, Jones M, Bowman J, Tian C, Spano JP. POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin-paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma. Front Oncol. 2022 Aug 24;12:935383. doi: 10.3389/fonc.2022.935383. eCollection 2022.","pmid":"36091159","type":"DERIVED"}],"start_date":{"date":"2020-11-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).","url":"https://clinicaltrials.gov/study/NCT04472429"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/interaact-2-nct04472429"}